Prostate cancer is the second most common cancer among men worldwide, following lung cancer. In the United States alone, nearly 300,000 new cases are diagnosed annually. While reducing testosterone and other male hormones can be an effective treatment for prostate cancer, this approach becomes ineffective once the disease progresses to metastatic castration-resistant prostate cancer (mCRPC). At this stage, the cancer advances quickly and becomes resistant to conventional hormonal therapies and chemotherapy.
Targeted cancer therapies: Getting radioactive atoms to accumulate in tumors
Tech News
-
Free Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
Smart buildings: What happens to our free will when tech makes choices for us?
-
Screenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
Darknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
Privacy violations undermine the trustworthiness of the Tim Hortons brand
-
Why Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars